Discontinued — last reported Q3 '14
Amgen Intangible Assets Gross (Excluding Goodwill) decreased by 0.7% to $55.01B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.1%, from $56.19B to $55.01B. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests significant investment in R&D or strategic acquisitions of intellectual property, which may drive future revenue growth.
This represents the total acquisition cost of non-physical assets such as patents, trademarks, and licenses, excluding g...
A key metric for pharma and tech companies to compare the depth of their patent portfolios and intellectual property moats.
intangible_assets_gross_excluding_goodwill| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $56.45B | $56.23B | $56.22B | $56.19B | $56.12B | $55.35B | $55.41B | $55.01B |
| QoQ Change | — | -0.4% | -0.0% | -0.0% | -0.1% | -1.4% | +0.1% | -0.7% |
| YoY Change | — | — | — | — | -0.6% | -1.6% | -1.4% | -2.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.